Role of PET/CT in Ovarian Cancer
|
|
- Lillian McLaughlin
- 6 years ago
- Views:
Transcription
1 Residents Section Structured Review rticle Prakash et al. PET/T in Ovarian ancer Residents Section Structured Review rticle Downloaded from by on 04/26/18 from IP address opyright RRS. For personal use only; all rights reserved Priyanka Prakash 1 armel G. ronin Michael. lake Prakash P, ronin G, lake M Keywords: ovarian cancer, PET/T DOI: /JR Received October 18, 2009; accepted after revision November 18, ll authors: Department of Radiology, Massachusetts General Hospital and Harvard Medical School, 55 Fruit St., oston, M ddress correspondence to M.. lake (mblake2@partners.org). WE This is a Web exclusive article. JR 2010; 194:W464 W X/10/1946 W464 merican Roentgen Ray Society Role of PET/T in Ovarian ancer OJETIVE. The purpose of this article is to review the role of FDG PET/T in ovarian cancer, which is the leading cause of death among gynecologic cancers. onclusion. FDG PET/T can significantly modify the assessment of the extent of primary and recurrent ovarian cancer and, hence, often alters patient management substantially. FDG PET/T has thus become a critical tool for the preoperative evaluation of women with primary ovarian cancer and for postoperative follow-up assessment for evidence of recurrence in these patients. mong gynecologic cancers, ovarian cancer is the leading cause of death. ccording to the estimates by the merican ancer Society, ovarian cancer accounted for 3% of new cases of female malignancies and 5% of cancer-related deaths in 2009 in the United States [1]. Imaging, especially ultrasound and T, has become a critical part of the evaluation of patients with ovarian cancer. s for many other malignancies, the role of FDG PET and PET/T is being extensively studied for the evaluation of ovarian malignancy. In this article, we review the role of FDG PET/T in ovarian cancer. Imaging Technique t our institution, PET/T examinations are performed on an integrated PET/ T scanner that includes an MDT and a PET system with 3D lutetium oxyorthosilicate crystals. Patients are instructed to fast for a minimum of 4 hours before scanning, and blood glucose should be < 200 mg/dl before the injection of FDG. fter attaining the desired blood sugar levels, FDG is administered within the dose range of mi ( Mq), according to patient weight. pproximately an hour after administration of the tracer, attenuation correction T is initially performed from the skull base to mid-thigh. This T is used for mainly anatomic localization of FDG and attenuation correction purposes. Immediately after the T, PET images are acquired in 2D mode over the same anatomic region start- ing from midthigh. The attenuation correction T images are then fused with PET, and fused PET/T is used for visual interpretation and tumor volume measurements. In addition, a diagnostic neck, chest, and abdominal T examination with IV administration of 120 ml of iodinated contrast medium (iopamidol 370 mg [Iopamiro, racco Diagnostics]) is also performed. The attenuation correction T parameters for a 16-MDT are as follows: 0.5 seconds per gantry rotation time, detector configuration of mm, 10-mm slice thickness, 40 m, and 120 kvp. The corresponding imaging parameters for diagnostic T examination on the 16-MDT are 120 kvp, 200 reference ms (an imaging quality parameter for applying automatic exposure control technique [RE Dose 4D, Siemens Healthcare]), detector configuration of mm, gantry rotation time of 0.5 second, 2.5-mm slice thickness at 2.5- mm slice interval, and a pitch of 1.2. For 64- MDT, the attenuation correction T parameters are 120 kvp, m, 1.5 pitch, 0.5 second per gantry rotation time, detector configuration of mm, and 10-mm slice thickness. The diagnostic 64-MDT is performed at 120 kvp, 200 ms, 0.75 pitch, 0.5 second per gantry rotation time, detector configuration of mm, and 2.5-mm slice thickness. Imaging Features Physiologic versus pathologic uptake In premenopausal women, the amount of FDG uptake in the ovaries varies with the W464 JR:194, June 2010
2 PET/T in Ovarian ancer Downloaded from by on 04/26/18 from IP address opyright RRS. For personal use only; all rights reserved phase of menstrual cycle, with physiologic uptake particularly present in the early luteal phase (Fig. 1). This can be avoided by performing the scan just subsequent to menstruation. Moreover, the typical appearance of physiologic uptake in the ovary is spherical or discoid with smooth margins and is located above the urinary bladder or around the uterus, which can be used to distinguish it from pathologic changes. In addition, the characteristic T appearance of a small rimenhancing cyst, the absence of any lymph nodes, and concordance with the appropriate stage of menstrual cycle are also helpful E D Fig year-old-woman with ovarian cancer. and, Transverse PET/T () and PET () images show presence of physiologic PET activity in right ovary. and D, Similar findings can be seen in coronal PET/ T () and PET (D) images. E, orresponding axial T image shows corpus luteum cyst (arrow) in corresponding ovary. in recognizing the benign nature of the uptake [2]. In postmenopausal ovaries, however, any ovarian uptake is pathologic, whether benign or malignant. enign versus malignant lesions few studies have evaluated the role of PET for early diagnosis of ovarian cancer but have reported a low sensitivity (58%) and specificity (76%) [3]. However, with the advent of PET/T, the anatomic and metabolic data can be acquired in the same setting and provide precise localization of suspicious areas of increased FDG uptake and help with the assessment of incidental ovarian findings. Ovarian lesions will show variable increase in FDG uptake on PET/T. In a study by astellucci et al. [4], a focally increased standardized uptake value (SUV) of 3 or higher in the ovary was considered positive for ovarian malignancy, whereas an SUV of 2.7 or lower was considered benign. Moreover, differentiation between benign and malignant uptake on PET can be aided by the contemporaneously acquired T scan on the basis of the characteristic pattern and location of FDG uptake and the lack of discrete lymph nodes in patients with benign lesions. That study reported a sensitivity of 87% and specificity of 100% for differentiating benign from malignant ovarian cancer using these criteria [4]. lso, three of four falsenegative PET/T scans in this study had primary tumors measuring 5 mm. In another study, PET/T was found to have a sensitivity of 80% and specificity of 97% for the diagnosis of malignancy in the contralateral ovary in patients with primary ovarian cancer [5]. Thus, although PET/T has a high specificity for lesions greater than 5 mm in size, its sensitivity is much lower than that of sonography. Hence, PET/T has not replaced sonography for the screening of ovarian cancer. However, because of its high specificity, FDG PET/T may be used to confirm the diagnosis and assess for metastases before the patient undergoes surgical evaluation. Staging of Ovarian ancer Ovarian cancer is staged surgically according to the International Federation of Gynecol- JR:194, June 2010 W465
3 Prakash et al. Downloaded from by on 04/26/18 from IP address opyright RRS. For personal use only; all rights reserved TLE 1: International Federation of Obstetric Gynecology (FIGO) and TNM Staging Systems for Ovarian ancer Tumor Type, TNM ategory FIGO Stage Description Primary tumor (T) TX T0 Primary tumor cannot be assessed No evidence of primary tumor T1 I Tumor limited to ovaries (one or both) T1a I Tumor limited to one ovary; capsule intact, no tumor on ovarian surface; no malignant cells in ascites or peritoneal washing T1b I Tumor limited to both ovaries T1c I Tumor limited to one or both ovaries with any of the following: capsule ruptured, tumor on ovarian surface, malignant cells in ascites or peritoneal washings T2 II Tumor involves one or both ovaries with pelvic extension or implants T2a II Extension or implants on uterus or tube(s); no malignant cells in ascites or peritoneal washings T2b II Extension to or implants on other pelvic tissues; no malignant cells in ascites or peritoneal washings T2c II Pelvic extension or implants (T2a or T2b) with malignant cells in ascites or peritoneal washings T3 III Tumor involves one or both ovaries with microscopically confirmed peritoneal metastasis outside the pelvis T3a III Microscopic peritoneal metastasis beyond pelvis (no macroscopic tumor) T3b III Macroscopic peritoneal metastasis beyond pelvis 2 cm in greatest dimension T3c III Peritoneal metastasis beyond pelvis > 2 cm in greatest dimension or regional lymph node metastasis Regional lymph nodes (N) NX N0 Regional lymph nodes cannot be assessed No regional lymph node metastasis N1 III Regional lymph node metastasis Distant metastasis (M) MX M0 Distant metastasis cannot be assessed No distant metastasis M1 IV Distant metastasis (excludes peritoneal metastasis) TLE 2: Summary of TNM and International Federation of Obstetrics Gynecology Staging of Ovarian ancer Stage Grouping Primary Tumor Stage (T) Regional Lymph Node Stage (N) Distant Metastasis Stage (M) I T1 N0 M0 I T1a N0 M0 I T1b N0 M0 I T1c N0 M0 II T2 N0 M0 II T2a N0 M0 II T2b N0 M0 II T2c N0 M0 III T3 N0 M0 III T3a N0 M0 III T3b N0 M0 III T3c N0 M0 ny T N1 M0 IV ny T ny N M1 ogy and Obstetrics TNM staging [6] (Tables 1 and 2). T has been the imaging technique of choice in the primary staging of women with ovarian cancer preoperatively. Recent studies have shown that FDG PET, when used in conjugation with T, is useful in evaluating distant metastases as well as equivocal lesions [4, 5]. PET/T had high sensitivity in identifying peritoneal deposits larger than 1 cm and lymph nodes larger than 7 mm. It has been shown to increase the pretreatment staging accuracy to 69 75% compared with 53 55% with T alone (Figs. 2 and 3) [4]. lthough both of these studies show definite evidence of improved accuracy in staging with the use of PET/T, they also suggest that PET/T is particularly useful in distinguishing patients with stages III IV cancer from those with stages I III cancer. For this classification, the specificity, sensitivity, and accuracy of FDG PET/T was 91%, 100%, and 98%, respectively, in comparison with 64%, 97%, and 88% for T [5]. Thus, PET/T can help W466 JR:194, June 2010
4 PET/T in Ovarian ancer Downloaded from by on 04/26/18 from IP address opyright RRS. For personal use only; all rights reserved in identifying the clinically important group of patients for whom optimal debulking is not possible and who thus need to undergo preoperative chemotherapy. Posttreatment follow-up The survival of patients after treatment has increased significantly as a result of advances in the surgical and chemotherapy drugs. However, this lengthened survival has simultaneously increased the incidence of recurrence, and it has been reported that 75% of patients with ovarian cancer have a likelihood of disease relapse [7]. Early diagnosis of recurrence and exact anatomic localization of metastatic disease are crucial for Fig year-old woman with primary ovarian cancer. and, Transverse PET/T images show abnormal FDG uptake in pelvis corresponding to areas of malignancy., orresponding T image depicts soft-tissue masses (arrow) in areas of FDG uptake and ascites (asterisk) also present. Fig year-old woman (same patient as in Fig. 2) with primary ovarian malignancy. and, Transverse PET/T images show marked FDG uptake in peritoneal soft tissue, indicating presence of peritoneal carcinomatosis along with malignant ascites., orresponding axial T image shows presence of both ascites and peritoneal carcinomatosis (arrow). determination of the best treatment strategy. Even though the -125 tumor marker has high sensitivity for early diagnosis of recurrence in epithelial ovarian cancer; it does not give any information about the extent or location of recurrence. Moreover, it has a poor negative predictive value [8]. T has been the standard imaging technique for evaluation of suspected recurrence of ovarian cancer. ccuracy of T however, has varied from 38% to 88% in the published literature [9]. Recently, PET/T has been extensively studied and has been shown to add confidence and accuracy to the diagnosis (Figs. 4, 5, and 6). The patient-based sensitivity, specificity, and accuracy of PET/T have ranged from 53% to 97%, 80% to 97%, and 68% to 92%, respectively [9 11]. Sironi et al. [9] have reported the lowest sensitivity of 53%. However, all the lesions missed on PET/T in that study were < 5 mm in size, which is below the resolution of PET/T and indeed essentially any other currently available imaging technique. In addition, PET/T has a high positive predictive value of 89% 98% for recurrence of ovarian cancer. Iagaru et al. [12] classified the lesions of recurrent ovarian malignancy into pelvic and extrapelvic lesions and found that PET/T is much more sensitive for extrapelvic lesions than for pelvic lesions. This is true, in part, because the physiologic uptake in the bladder obscures the pathologic uptake in the JR:194, June 2010 W467
5 Prakash et al. Downloaded from by on 04/26/18 from IP address opyright RRS. For personal use only; all rights reserved Fig year-old woman with primary ovarian cancer. and, oronal PET/T images depict mm FDG-avid soft-tissue mass in liver, which is consistent with metastasis., orresponding coronal T image shows presence of metastatic lesion in liver (arrow). D E Fig year-old woman with primary ovarian cancer., Transverse PET/T image in soft-tissue window shows presence of intensely avid soft-tissue nodule in right hemipelvis adjacent to right ureter, representing recurrent ovarian cancer., Same image on bone windows shows presence of intense uptake in right paraspinal region secondary to inflammatory changes following laminectomy., Image shows false-positive uptake, which might be misinterpreted as metastasis and thus could be pitfall of PET alone without T for clarification. D, orresponding axial T image in softtissue window shows presence of nodule in retroperitoneum (arrow). E, xial T image on bone window shows presence of postsurgical changes in vertebra (asterisk) associated with false-positive FDG uptake. pelvis. lso, the postsurgical inflammatory changes in the pelvis can lead to false-positive areas of uptake on PET/T. PET/T not only helps in diagnosing recurrence but also affects subsequent management. With its ability to precisely localize the lesion as well as the extent of recurrence and distant metastases, PET/T plays an important role in restaging for recurrent ovarian cancer. Fagotti et al. [13] studied the ability of PET/T to predict the possibility of optimal cytoreduction in recurrent ovarian cancer and reported an accuracy of 79%, sensitivity of 93%, specificity of 56%, positive predictive value of 77%, and negative predictive value of 83% and, hence, good efficacy of PET/T in planning surgical treatment of patients with recurrent W468 JR:194, June 2010
6 PET/T in Ovarian ancer Downloaded from by on 04/26/18 from IP address opyright RRS. For personal use only; all rights reserved ovarian cancer. PET/T was found to be comparable to staging laparoscopy for this purpose. gain, the false-negative results on PET/T in that study were small peritoneal implants < 7 mm in size. Mangili et al. [14] not only reported a much higher sensitivity of PET/T (91%) in comparison with contrast-enhanced T (62%) alone for diagnosis of recurrent ovarian cancer, they also showed that the result on PET/T changes the treatment technique for 44% of the patients. In another similar study, findings on PET/T were found to significantly change the management of recurrent ovarian cancer in 57% of the patients [15]. Fig year-old woman with history of ovarian cancer undergoing imaging for follow-up. and, Transverse PET/T images show presence of multiple soft-tissue nodules in mid pelvis with increased FDG uptake consistent with recurrence of patient s known ovarian cancer., orresponding axial T image shows presence of nodules in pelvis corresponding to areas of FDG uptake (arrow). Fig year-old-woman (same patient as in Fig. 6) with history of ovarian cancer undergoing imaging for follow-up. and, Transverse PET/T images show presence of increased FDG uptake along anterior abdominal wall corresponding to ill-defined soft-tissue density at site of previous surgery (note presence of surgical clips). ecause previous surgery in this patient was 2 years earlier, new uptake was consistent with recurrence of patient s known ovarian cancer., orresponding axial T image shows presence of soft tissue adjacent to surgical clips (arrow). dvantages of the imaging technique FDG PET/T has high positive predictive value and accuracy for diagnosing primary as well as recurrent ovarian cancer. Moreover, it helps significantly in planning the treatment of patients in both categories. Pitfalls or limitations of the imaging technique FDG PET/T is limited in its ability to identify lesions < 1 cm, in particular, those smaller than 5 mm, leading to a false-negative rate of 5% 10%. Moreover, in the abdomen and pelvis, a large number of misregistrations can occur as a result of the physiologic uptake in bowel and bladder and as a result of bowel peristalsis; knowledge of these issues and careful review are required for accurate interpretation. Similarly, in recurrent ovarian cancer, PET/T is somewhat limited in its ability to distinguish postoperative inflammatory changes from tumor recurrence or persistence (Fig. 5b), but correlation with the T findings and the patient s history and examination helps to determine the significance and thus guide management. onclusion FDG PET/T can significantly modify the assessment of the extent of primary and recurrent ovarian cancer and, hence, often alters patient management substantially. FDG PET/T has thus become a critical tool for the preoperative evaluation of women with primary ovarian cancer and for postoperative follow-up assessment for evidence of recurrence in these patients (Fig. 7). References 1. Jemal, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. ancer statistics, ancer J lin 2009; 59: Liu Y. enign ovarian and endometrial uptake on FDG PET-T: patterns and pitfalls. nn Nucl JR:194, June 2010 W469
7 Prakash et al. Med 2009; 23: : Sebastian S, Lee SI, Horowitz NS, et al. PET-T 3. Fenchel S, Grab D, Nuessle K. symptomatic ad- 7. Greenlee RT, Hill Harmon M, Murray T, Thun vs T alone in ovarian cancer recurrence. bdom Downloaded from by on 04/26/18 from IP address opyright RRS. For personal use only; all rights reserved nexal masses: correlation of FDG PET and histopathologic findings. Radiology 2002; 223: astellucci P, Perrone M, Picchio M. Diagnostic accuracy of 18 F-FDG PET/T in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology. Nucl Med ommun 2007; 28: Kitajima K, Murakami K, Yamasaki E. Diagnostic accuracy of integrated FDG-PET/contrast-enhanced T in staging ovarian cancer: comparison with enhanced T. Eur J Nucl Med Mol Imaging 2008; 35: Mironov S, kin O, Pandit-Taskar N, Hann LE. Ovarian cancer. Radiol lin North m 2007; M. ancer statistics, ancer J lin 2001; 51: Rustin GJ, Nelstrop E, Tuxen MK, Lambert HE. Defining progression of ovarian carcinoma during follow-up according to 125: a North Thames Ovary Group study. nn Oncol 1996; 7: Sironi S, Messa, Mangili G, et al. Integrated FDG PET/T in patients with persistent ovarian cancer: correlation with histological findings. Radiology 2004; 233: hung HH, Kang WJ, Kim JW, et al. Role of [ 18 F] FDG PET/T in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings. Eur J Nucl Med Mol Imaging 2007; 34: Imaging 2008; 33: Iagaru H, Mittra ES, McDougall IR, et al. 18 F-FDG PET/T evaluation of patients with ovarian carcinoma. Nucl Med ommun 2008; 29: Fagotti, Fanfani F, Rositto, et al. treatment selection protocol for recurrent ovarian cancer patients: the role of FDG-PET/T and staging laparoscopy. Oncology 2008; 75: Mangili G, Picchio M, Sironi S. Integrated PET/ T as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer. Eur J Nucl Med Mol Imaging 2007; 34: Simcock, Neesham D, Quinn M. The impact of PET/T in the management of recurrent ovarian cancer. Gynecol Oncol 2006; 103: W470 JR:194, June 2010
Spectrum of FDG PET/CT Findings of Uterine Tumors
Nuclear Medicine and Molecular Imaging Pictorial Essay Kitajima et al. FDG PET/CT of Uterine Tumors Nuclear Medicine and Molecular Imaging Pictorial Essay Downloaded from www.ajronline.org by 37.44.205.17
More informationFDG-PET/CT in Gynaecologic Cancers
Friday, August 31, 2012 Session 6, 9:00-9:30 FDG-PET/CT in Gynaecologic Cancers (Uterine) cervical cancer Endometrial cancer & Uterine sarcomas Ovarian cancer Little mermaid (Edvard Eriksen 1913) honoring
More informationPET/CT in Gynaecological Cancers. Stroobants Sigrid, MD, PhD Departement of Nuclear Medicine University Hospital,Antwerp
PET/CT in Gynaecological Cancers Stroobants Sigrid, MD, PhD Departement of Nuclear Medicine University Hospital,Antwerp Cervix cancer Outline of this talk Initial staging Treatment monitoring/guidance
More informationStaging recurrent ovarian cancer with 18 FDG PET/CT
ONCOLOGY LETTERS 5: 593-597, 2013 Staging recurrent ovarian cancer with FDG PET/CT SANJA DRAGOSAVAC 1, SOPHIE DERCHAIN 2, NELSON M.G. CASERTA 3 and GUSTAVO DE SOUZA 2 1 DIMEN Medicina Nuclear and PET/CT
More informationFDG-PET Findings in an Ovarian Endometrioma: A Case Report
FDG-PET Findings in an Ovarian Endometrioma: A Case Report Jia-Huei Lin 1, Victor Chit-kheng Kok 2, Jian-Chiou Su 3 1 Department of Nuclear medicine, Kuang Tien General Hospital, Sha-Lu, Taichung, Taiwan
More informationThe role of PET/CT in the management of Gynaecological Malignancies. Dr Patrick Fielding Consultant Radiologist PETIC UHW 19 th November 2010
The role of PET/CT in the management of Gynaecological Malignancies Dr Patrick Fielding Consultant Radiologist PETIC UHW 19 th November 2010 Thank you! 1998-2003 2003-2006 2006-2010 ABMU LHB Cheltenham
More informationFDG-PET value in deep endometriosis
Gynecol Surg (2011) 8:305 309 DOI 10.1007/s10397-010-0652-6 ORIGINAL ARTICLE FDG-PET value in deep endometriosis A. Setubal & S. Maia & C. Lowenthal & Z. Sidiropoulou Received: 3 December 2010 / Accepted:
More informationPet Scan And Gynaecological Malignancies: Hospital Sultanah Bahiyah Experience
ORIGINAL ARTICLE Pet Scan And Gynaecological Malignancies: Hospital Sultanah Bahiyah Experience T Shahila, MMED (O&G), M N Rushdan, MMED (O&G) Gynaecological Oncology Unit, Department of Obstetrics & Gynaecology,
More informationPET/CT Frequently Asked Questions
PET/CT Frequently Asked Questions General Q: Is FDG PET specific for cancer? A: No, it is a marker of metabolism. In general, any disease that causes increased metabolism can result in increased FDG uptake
More informationColorectal Cancer and FDG PET/CT
Hybrid imaging in colorectal & esophageal cancer Emmanuel Deshayes IAEA WorkShop, November 2017 Colorectal Cancer and FDG PET/CT 1 Clinical background Cancer of the colon and rectum is one of the most
More informationDisclosure. Acknowledgement. What is the Best Workup for Rectal Cancer Staging: US/MRI/PET? Rectal cancer imaging. None
What is the Best Workup for Rectal Cancer Staging: US/MRI/PET? Zhen Jane Wang, MD Assistant Professor in Residence UC SF Department of Radiology Disclosure None Acknowledgement Hueylan Chern, MD, Department
More informationOriginal Report. Sacral Fractures: A Potential Pitfall of FDG Positron Emission Tomography
Downloaded from www.ajronline.org by 37.44.199.199 on 12/24/17 from IP address 37.44.199.199. opyright RRS. For personal use only; all rights reserved Laura M. Fayad 1 hristian ohade Richard L. Wahl Elliot
More informationH&E, IHC anti- Cytokeratin
Cat No: OVC2281 - Ovary cancer tissue array Lot# Cores Size Cut Format QA/QC OVC228101 228 1.1mm 4um 12X19 H&E, IHC anti- Cytokeratin Recommended applications: For Research use only. RNA or protein ovary
More informationClinical summary. Male 30 year-old with past history of non-seminomous germ cell tumour. Presents with retroperitoneal lymphadenopathy on CT.
Clinical summary Male 30 year-old with past history of non-seminomous germ cell tumour. Presents with retroperitoneal lymphadenopathy on CT. For restaging PET/CT. PET/CT findings No significant FDG uptake
More informationOvarian Tumors. Andrea Hayes-Jordan MD FACS, FAAP Section Chief, Pediatric Surgery/Surgical Onc. UT MD Anderson Cancer Center
Ovarian Tumors Andrea Hayes-Jordan MD FACS, FAAP Section Chief, Pediatric Surgery/Surgical Onc. UT MD Anderson Cancer Center Case 13yo female with abdominal pain Ultrasound shows huge ovarian mass Surgeon
More informationJMSCR Vol 05 Issue 06 Page June 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i6.29 MRI in Clinically Suspected Uterine and
More informationPET CT for Staging Lung Cancer
PET CT for Staging Lung Cancer Rohit Kochhar Consultant Radiologist Disclosures Neither I nor my immediate family members have financial relationships with commercial organizations that may have a direct
More informationCervical Cancer: 2018 FIGO Staging
Cervical Cancer: 2018 FIGO Staging Jonathan S. Berek, MD, MMS Laurie Kraus Lacob Professor Stanford University School of Medicine Director, Stanford Women s Cancer Center Senior Scientific Advisor, Stanford
More informationBreast Cancer PET/CT Imaging Protocol
Breast Cancer PET/CT Imaging Protocol Scanning Protocol: Patients are scanned from the top of the neck through the pelvis. Arms-up position is used to avoid beam-hardening artifact in the chest and abdomen.
More informationIMAGING GUIDELINES - COLORECTAL CANCER
IMAGING GUIDELINES - COLORECTAL CANCER DIAGNOSIS The majority of colorectal cancers are diagnosed on colonoscopy, with some being diagnosed on Ba enema, ultrasound or CT. STAGING CT chest, abdomen and
More informationFDG PET/CT STAGING OF LUNG CANCER. Dr Shakher Ramdave
FDG PET/CT STAGING OF LUNG CANCER Dr Shakher Ramdave FDG PET/CT STAGING OF LUNG CANCER FDG PET/CT is used in all patients with lung cancer who are considered for curative treatment to exclude occult disease.
More informationImaging in gastric cancer
Imaging in gastric cancer Gastric cancer remains a deadly disease because of late diagnosis. Adenocarcinoma represents 90% of malignant tumors. Diagnosis is based on endoscopic examination with biopsies.
More informationRevised RECIST Guideline Version 1.1: What Oncologists Want to Know and What Radiologists Need to Know
Special rticle Pictorial Essay Nishino et al. Revised REIST Guideline Special rticle Pictorial Essay Downloaded from www.ajronline.org by 46.3.203.167 on 11/20/17 from IP address 46.3.203.167. opyright
More informationobjectives Pitfalls and Pearls in PET/CT imaging Kevin Robinson, DO Assistant Professor Department of Radiology Michigan State University
objectives Pitfalls and Pearls in PET/CT imaging Kevin Robinson, DO Assistant Professor Department of Radiology Michigan State University To determine the regions of physiologic activity To understand
More informationPET/CT for Adrenal Assessment
Residents Section Structured Review rticle lake et al. PET/CT of the drenal Glands Residents Section Structured Review rticle Michael. lake 1 Priyanka Prakash Carmel G. Cronin lake M, Prakash P, Cronin
More informationMEASUREMENT OF EFFECT SOLID TUMOR EXAMPLES
MEASUREMENT OF EFFECT SOLID TUMOR EXAMPLES Although response is not the primary endpoint of this trial, subjects with measurable disease will be assessed by standard criteria. For the purposes of this
More informationFDG-PET/CT for cancer management
195 REVIEW FDG-PET/CT for cancer management Hideki Otsuka, Naomi Morita, Kyo Yamashita, and Hiromu Nishitani Department of Radiology, Institute of Health Biosciences, The University of Tokushima, Graduate
More informationAmerican Journal of Oral Medicine and Radiology
American Journal of Oral Medicine and Radiology e - ISSN - XXXX-XXXX ISSN - 2394-7721 Journal homepage: www.mcmed.us/journal/ajomr ULTRASONOGRAPHIC EVALUATION OF ADNEXAL MASSES Nageswar Rao* Professor,
More informationDr Sneha Shah Tata Memorial Hospital, Mumbai.
Dr Sneha Shah Tata Memorial Hospital, Mumbai. Topics covered Lymphomas including Burkitts Pediatric solid tumors (non CNS) Musculoskeletal Ewings & osteosarcoma. Neuroblastomas Nasopharyngeal carcinomas
More informationCT PET SCANNING for GIT Malignancies A clinician s perspective
CT PET SCANNING for GIT Malignancies A clinician s perspective Damon Bizos Head, Surgical Gastroenterology Charlotte Maxeke Johannesburg Academic Hospital Case presentation 54 year old with recent onset
More informationWhat is endometrial cancer?
Uterine cancer What is endometrial cancer? Endometrial cancer is the growth of abnormal cells in the lining of the uterus. The lining is called the endometrium. Endometrial cancer usually occurs in women
More informationStaging and Treatment Update for Gynecologic Malignancies
Staging and Treatment Update for Gynecologic Malignancies Bunja Rungruang, MD Medical College of Georgia No disclosures 4 th most common new cases of cancer in women 5 th and 6 th leading cancer deaths
More informationEDUCATIONAL COMMENTARY CA 125. Learning Outcomes
EDUCATIONAL COMMENTARY CA 125 Learning Outcomes Upon completion of this exercise, participants will be able to: discuss the use of CA 125 levels in monitoring patients undergoing treatment for ovarian
More informationPET-CT findings in surgically transposed ovaries
The British Journal of Radiology, 79 (2006), 110 115 1,2,3 R ZISSIN, MD, 1 U METSER, MD, 1 H LERMAN, MD, 1 G LIEVSHITZ, MD, 4 T SAFRA, MD and 1,3 E EVEN-SAPIR, MD, PhD Department of 1 Nuclear Medicine
More informationGenitourinary Imaging Pictorial Essay
Genitourinary Imaging Pictorial Essay Patil et al. PET/CT of Transitional Cell Carcinoma Genitourinary Imaging Pictorial Essay Downloaded from www.ajronline.org by 37.44.193.45 on 01/04/18 from IP address
More informationLos Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010
Los Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010 Self Assessment Module on Nuclear Medicine and PET/CT Case Review FDG PET/CT IN LYMPHOMA AND MELANOMA Submitted
More informationGynecologic Cancer Surveillance and Survivorship: Informing Practice and Policy
Gynecologic Cancer Surveillance and Survivorship: Informing Practice and Policy Stephanie Yap, M.D. University Gynecologic Oncology Northside Cancer Institute Our Learning Objectives Review survival rates,
More informationDownloaded from by on 12/01/17 from IP address Copyright ARRS. For personal use only; all rights reserved
Head and Neck Imaging Kapoor et al. 18F FDG PET/T of Head and Neck ancers Downloaded from www.ajronline.org by 46.3.199.27 on 12/01/17 from IP address 46.3.199.27. opyright RRS. For personal use only;
More informationcysts is possible if imaging findings are correlated with appropriate clinical findings [1]. The
Pictorial Essay Imaging of Peritoneal Inclusion Cysts Kiran. Jain1 lthough fairly common, peritoneal inclusion cysts are less well-recognized entities on imaging of the female pelvis. Peritoneal inclusion
More informationOriginal Article Validity of CT Scan for Ovarian Carcinoma Pak Armed Forces Med J 2015; 65(4): Anila Faisal, Mahjabeen Mehmood Kamal
Original Article Validity of CT Scan for Ovarian Carcinoma Pak Armed Forces Med J 2015; 65(4): 469-73 VALIDITY OF COMPUTED TOMOGRAPHY SCAN FOR THE DIAGNOSIS OF OVARIAN CARCINOMA AND ITS STAGES Anila Faisal,
More informationMUSCLE - INVASIVE AND METASTATIC BLADDER CANCER
10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg
More information3 Summary of clinical applications and limitations of measurements
CA125 (serum) 1 Name and description of analyte 1.1 Name of analyte Cancer Antigen 125 (CA125) 1.2 Alternative names Mucin-16 1.3 NLMC code To follow 1.4 Description of analyte CA125 is an antigenic determinant
More informationRecurrent Ovarian Cancer: Spectrum of Imaging Findings
Recurrent Ovarian Cancer Women s Imaging Pictorial Essay Downloaded from www.ajronline.org by 80.243.130.157 on 03/08/18 from IP address 80.243.130.157. Copyright RRS. For personal use only; all rights
More informationGenitourinary Imaging Pictorial Essay
rown et al. MRI of the Female Pelvis Genitourinary Imaging Pictorial Essay Downloaded from www.ajronline.org by 37.44.202.41 on 12/17/17 from IP address 37.44.202.41. Copyright RRS. For personal use only;
More informationTHE ROLE OF CONTEMPORARY IMAGING AND HYBRID METHODS IN THE DIAGNOSIS OF CUTANEOUS MALIGNANT MELANOMA(CMM) AND MERKEL CELL CARCINOMA (MCC)
THE ROLE OF CONTEMPORARY IMAGING AND HYBRID METHODS IN THE DIAGNOSIS OF CUTANEOUS MALIGNANT MELANOMA(CMM) AND MERKEL CELL CARCINOMA (MCC) I.Kostadinova, Sofia, Bulgaria CMM some clinical facts The incidence
More informationStaging Colorectal Cancer
Staging Colorectal Cancer CT is recommended as the initial staging scan for colorectal cancer to assess local extent of the disease and to look for metastases to the liver and/or lung Further imaging for
More informationRyan Niederkohr, M.D. Slides are not to be reproduced without permission of author
Ryan Niederkohr, M.D. CMS: PET/CT CPT CODES 78814 Limited Area (e.g., head/neck only; chest only) 78815 78816 Regional (skull base to mid-thighs) True Whole Body (skull vertex to feet) SELECTING FIELD
More informationIndex. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic
More informationDirect Comparison of 18 F-FDG PET and PET/CT in Patients with Colorectal Carcinoma
Direct Comparison of F-FDG PET and PET/CT in Patients with Colorectal Carcinoma Christian Cohade, MD; Medhat Osman, MD, PhD; Jeffrey Leal, BA; and Richard L. Wahl, MD Division of Nuclear Medicine, Russell
More informationGENERAL DATA. Sex : female Age : 40 years old Marriage status : married
GENERAL DATA Sex : female Age : 40 years old Marriage status : married CHIEF COMPLAINT Bilateral ovarian tumors discovered by sonography accidentally PRESENT ILLNESS 2003-06-26 :bilateral ovarian tumors
More informationMPH Quiz. 1. How many primaries are present based on this pathology report? 2. What rule is this based on?
MPH Quiz Case 1 Surgical Pathology from hysterectomy performed July 11, 2007 Final Diagnosis: Uterus, resection: Endometrioid adenocarcinoma, Grade 1 involving most of endometrium, myometrial invasion
More information11/10/2015. Prostate cancer in the U.S. Multi-parametric MRI of Prostate Diagnosis and Treatment Planning. NIH estimates for 2015.
Multi-parametric MRI of Prostate Diagnosis and Treatment Planning Temel Tirkes, M.D. Associate Professor of Radiology Director, Genitourinary Radiology Indiana University School of Medicine Department
More informationPET/CT for the evaluation of gynecological
PET/CT for the evaluation of gynecological cancer Gynecological cancer Barcelona, September 16 th 2018 Dr. Pilar Paredes, MD, PhD Nuclear Medicine Department Hospital Clínic Barcelona (Spain) PET/CT in
More informationPET IMAGING (POSITRON EMISSION TOMOGRAPY) FACT SHEET
Positron Emission Tomography (PET) When calling Anthem (1-800-533-1120) or using the Point of Care authorization system for a Health Service Review, the following clinical information may be needed to
More informationROLE OF PET-CT IN BREAST CANCER, GUIDELINES AND BEYOND. Prof Jamshed B. Bomanji Institute of Nuclear Medicine UCL Hospitals London
ROLE OF PET-CT IN BREAST CANCER, GUIDELINES AND BEYOND Prof Jamshed B. Bomanji Institute of Nuclear Medicine UCL Hospitals London CANCER Key facts Estimated 15.2 million new cases per year in 2015 worldwide
More informationExtrapulmonary Small Cell Carcinoma: A Pictorial Review
Nuclear Medicine and Molecular Imaging Original Research Howard Extrapulmonary Small ell arcinoma Special rticle Pictorial Essay ownloaded from www.ajronline.org by 37.44.206.3 on 01/23/18 from IP address
More informationEarly detection of prostate cancer (PCa) may feasibly lead
ORIGINAL ARTICLE C-11 Choline PET/CT Imaging for Differentiating Malignant From Benign Prostate Lesions Xin Li, MD,* Qi Liu, MD, PhD,* Muwen Wang, MD, PhD,* Xunbo Jin, MD,* Qingwei Liu, MD, PhD,* Shuzhan
More informationCA125 in the diagnosis of ovarian cancer: the art in medicine
CA125 in the diagnosis of ovarian cancer: the art in medicine Dr Marcia Hall Consultant Medical Oncology Mount Vernon Cancer Centre Hillingdon Hospital Wexham Park Hospital Epidemiology Ovarian cancer
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Cancer of the Ovary
North of Scotland Cancer Network Cancer of the Ovary Based on WOSCAN CMG with further extensive consultation within NOSCAN UNCONTROLLED WHEN PRINTED DOCUMENT CONTROL Prepared by NOSCAN Gynaecology Cancer
More information1 Introduction. 2 Materials and methods. LI Na 1 LI Yaming 1,* YANG Chunming 2 LI Xuena 1 YIN Yafu 1 ZHOU Jiumao 1
Nuclear Science and Techniques 20 (2009) 354 358 18 F-FDG PET/CT in diagnosis of skeletal metastases LI Na 1 LI Yaming 1,* YANG Chunming 2 LI Xuena 1 YIN Yafu 1 ZHOU Jiumao 1 1 Department of Nuclear Medicine,
More informationDoes serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study
Guo and Peng Journal of Ovarian Research (2017) 10:14 DOI 10.1186/s13048-017-0310-y RESEARCH Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian
More informationperformed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.
Hello, I am Maura Polansky at the University of Texas MD Anderson Cancer Center. I am a Physician Assistant in the Department of Gastrointestinal Medical Oncology and the Program Director for Physician
More informationGeneral history. Basic Data : Age :62y/o Date of admitted: Married status : Married
General history Basic Data : Age :62y/o Date of admitted:940510 Married status : Married General history Chief Complain : bilateral ovarian cyst incidentally being found out during pap smear. Present Illness
More informationUterine Smooth-Muscle Tumors with Unusual Growth Patterns: Imaging with Pathologic Correlation
ohen et al. Imaging Pathologic orrelation of Uterine Tumors Women s Imaging Pictorial Essay 246.fm 12/1/06 WOMEN S IMGING Daniel T. ohen 1,2 Esther Oliva 3 Peter F. Hahn 1 rlan F. Fuller, Jr. 4 Susanna
More informationProf. Dr. NAGUI M. ABDELWAHAB,M.D.; MARYSE Y. AWADALLAH, M.D. AYA M. BASSAM, Ms.C.
Role of Whole-body Diffusion MR in Detection of Metastatic lesions Prof. Dr. NAGUI M. ABDELWAHAB,M.D.; MARYSE Y. AWADALLAH, M.D. AYA M. BASSAM, Ms.C. Cancer is a potentially life-threatening disease,
More informationWinship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer
Winship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer Ira R. Horowitz, MD, SM, FACOG, FACS John D. Thompson Professor and Chairman Department of Gynecology
More informationPOSITRON EMISSION TOMOGRAPHY (PET)
Status Active Medical and Behavioral Health Policy Section: Radiology Policy Number: V-27 Effective Date: 08/27/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members should
More informationI have no financial relationships to disclose. I WILL NOT include discussion of investigational or off-label use of a product in my presentation.
Prostate t Cancer MR Report Disclosure Information Vikas Kundra, M.D, Ph.D. I have no financial relationships to disclose. I WILL NOT include discussion of investigational or off-label use of a g product
More informationEsophageal Cancer. What is the value of performing PET scan routinely for staging of esophageal cancers
Esophageal Cancer What is the value of performing PET scan routinely for staging of esophageal cancers What is the sensitivity and specificity of PET scan for metastatic lesions When should PET scan be
More informationCase Scenario 1. Pathology report Specimen from mediastinoscopy Final Diagnosis : Metastatic small cell carcinoma with residual lymphatic tissue
Case Scenario 1 Oncology Consult: Patient is a 51-year-old male with history of T4N3 squamous cell carcinoma of tonsil status post concurrent chemoradiation finished in October two years ago. He was hospitalized
More informationClinical indications for positron emission tomography
Clinical indications for positron emission tomography Oncology applications Brain and spinal cord Parotid Suspected tumour recurrence when anatomical imaging is difficult or equivocal and management will
More informationLYMPHATIC DRAINAGE IN THE HEAD & NECK
LYMPHATIC DRAINAGE IN THE HEAD & NECK Like other parts of the body, the head and neck contains lymph nodes (commonly called glands). Which form part of the overall Lymphatic Drainage system of the body.
More informationNew Visions in PET: Surgical Decision Making and PET/CT
New Visions in PET: Surgical Decision Making and PET/CT Stanley J. Goldsmith, MD Director, Nuclear Medicine Professor, Radiology & Medicine New York Presbyterian Hospital- Weill Cornell Medical Center
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Carcinoma of the Uterine Cervix
THIS DOCUMENT North of Scotland Cancer Network Carcinoma of the Uterine Cervix UNCONTROLLED WHEN PRINTED DOCUMENT CONTROL Prepared by A Kennedy/AG Macdonald/Others Approved by NOT APPROVED Issue date April
More informationEssentials of Clinical MR, 2 nd edition. 73. Urinary Bladder and Male Pelvis
73. Urinary Bladder and Male Pelvis Urinary bladder carcinoma is best locally staged with MRI. It is important however to note that a thickened wall (> 5 mm) is a non-specific finding seen in an underfilled
More informationOvarian Cancer Includes Epithelial, Fallopian Tube, Primary Peritoneal Cancer, and Ovarian Germ Cell Tumors
Ovarian Cancer Includes Epithelial, Fallopian Tube, Primary Peritoneal Cancer, and Ovarian Germ Cell Tumors Overview Ovarian epithelial cancer, fallopian tube cancer, and primary peritoneal cancer are
More informationبسم هللا الرحمن الرحيم. Prof soha Talaat
بسم هللا الرحمن الرحيم Ovarian tumors The leading indication for gynecologic surgery. Preoperative characterization of complex solid and cystic adnexal masses is crucial for informing patients about possible
More informationHighly accurate oncologic staging and restaging for early detection
Diagnostic Value of Diffusion-Weighted Imaging in Simultaneous 18 F-FDG PET/MR Imaging for Whole-Body Staging of Women with Pelvic Malignancies Johannes Grueneisen 1, Benedikt Michael Schaarschmidt 2,
More informationGeorge Cernile Artificial Intelligence in Medicine Toronto, ON. Carol L. Kosary National Cancer Institute Rockville, MD
George Cernile Artificial Intelligence in Medicine Toronto, ON Carol L. Kosary National Cancer Institute Rockville, MD Using RCA A system to convert free text pathology reports into a database of discrete
More informationValue of imaging study in predicting pelvic lymph node metastases of uterine cervical cancer
Original Article Radiat Oncol J 2017;35(4):340-348 pissn 2234-1900 eissn 2234-3156 Value of imaging study in predicting pelvic lymph node metastases of uterine cervical cancer Wonguen Jung, MD 1, Kyung
More informationMultitechnique Imaging Findings of Prolene Plug Hernia Repair
Genitourinary Imaging Pictorial Essay Cronin et al. Imaging of Prolene Plug Hernia Repair Genitourinary Imaging Pictorial Essay Carmel G. Cronin 1 Mukesh G. Harisinghani Onofrio Catalano Michael. lake
More informationNewcastle HPB MDM updated radiology imaging protocol recommendations. Author Dr John Scott. Consultant Radiologist Freeman Hospital
Newcastle HPB MDM updated radiology imaging protocol recommendations Author Dr John Scott. Consultant Radiologist Freeman Hospital This document is intended as a guide to aid radiologists and clinicians
More informationCase Reports: Tumor Detection by Diffusion-Weighted MRI and ADC-Mapping with Correlation to PET/CT Results
Case Reports: Tumor Detection by Diffusion-Weighted MRI and ADC-Mapping with Correlation to PET/CT Results Matthias Philipp Lichy, M.D.; Philip Aschoff, M.D.; Christina Pfannenberg, M.D.; Schlemmer Heinz-Peter,
More informationCarcinoma of the Urinary Bladder Histopathology
Carcinoma of the Urinary Bladder Histopathology Reporting Proforma (Radical & Partial Cystectomy, Cystoprostatectomy) Includes the International Collaboration on Cancer reporting dataset denoted by * Family
More informationCASE STUDY. Presented by: Jessica Pizzo. CFCC Sonography student Class of 2018
CASE STUDY Presented by: Jessica Pizzo CFCC Sonography student Class of 2018 Case Presentation April 4, 2017 56 yr old woman presented to ED with lower abdominal pain & swelling, along with constipation.
More informationMultidisciplinary management of retroperitoneal sarcomas
Multidisciplinary management of retroperitoneal sarcomas Eric K. Nakakura, MD UCSF Department of Surgery UCSF Comprehensive Cancer Center San Francisco, CA 7 th Annual Clinical Cancer Update North Lake
More informationRadiologic Pathologic Correlation of Intraosseous Lipomas. Tim Propeck 1, Mary Anne Bullard 1, John Lin 1, Kei Doi 2, William Martel 1
Downloaded from www.ajronline.org by 148.251.232.83 on 04/10/18 from IP address 148.251.232.83. opyright RRS. For personal use only; all rights reserved Radiologic Pathologic orrelation of Intraosseous
More informationThe Use of PET Scanning in Urologic Oncology
The Use of PET Scanning in Urologic Oncology Dr Nicholas C. Buchan Uro-oncology Fellow 1 2 Aims To understand the basic concepts underlying PET scanning. Understand the emerging role of PET Scanning for
More information1/25/13 Right partial nephrectomy followed by completion right radical nephrectomy.
History and Physical Case Scenario 1 45 year old white male presents with complaints of nausea, weight loss, and back pain. A CT of the chest, abdomen and pelvis was done on 12/8/12 that revealed a 12
More informationBone and CT Scans Are Complementary for Diagnoses of Bone Metastases in Breast Cancer When PET Scans Findings Are Equivocal: A Case Report
Bone and CT Scans Are Complementary for Diagnoses of Bone Metastases in Breast Cancer When Scans Findings Are Equivocal: A Case Report Yuk-Wah Tsang 1, Jyh-Gang Leu 2, Yen-Kung Chen 3, Kwan-Hwa Chi 1,4
More informationMUSCLE-INVASIVE AND METASTATIC BLADDER CANCER
MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction
More informationPulmonary Nodule Volumetric Measurement Variability as a Function of CT Slice Thickness and Nodule Morphology
CT of Pulmonary Nodules Chest Imaging Original Research Myria Petrou 1 Leslie E. Quint 1 in Nan 2 Laurence H. aker 3 Petrou M, Quint LE, Nan, aker LH Keywords: chest, lung disease, MDCT, oncologic imaging,
More informationRole of imaging in RCC. Ultrasonography. Solid lesion. Cystic RCC. Solid RCC 31/08/60. From Diagnosis to Treatment: the Radiologist Perspective
Role of imaging in RCC From Diagnosis to Treatment: the Radiologist Perspective Diagnosis Staging Follow up Imaging modalities Limitations and pitfalls Duangkamon Prapruttam, MD Department of Therapeutic
More informationFieldStrength. Leuven research is finetuning. whole body staging
FieldStrength Publication for the Philips MRI Community Issue 40 May 2010 Leuven research is finetuning 3.0T DWIBS for whole body staging The University Hospital of Leuven is researching 3.0T whole body
More informationRecommendations for cross-sectional imaging in cancer management, Second edition
www.rcr.ac.uk Recommendations for cross-sectional imaging in cancer management, Second edition Carcinoma of unknown primary origin (CUP) Faculty of Clinical Radiology www.rcr.ac.uk Contents Carcinoma of
More informationNuclear Medicine and Molecular Imaging Original Research
Nuclear Medicine and Molecular Imaging Original Research Bronstein et al. PET/CT in Metastatic Melanoma Nuclear Medicine and Molecular Imaging Original Research Yulia Bronstein 1 Chaan S. Ng 2 Eric Rohren
More informationVaginal Cancer Early Detection, Diagnosis, and Staging
Vaginal Cancer Early Detection, Diagnosis, and Staging Detection and Diagnosis Catching cancer early often allows for more treatment options. Some early cancers may have signs and symptoms that can be
More informationProf. Dr. Aydın ÖZSARAN
Prof. Dr. Aydın ÖZSARAN Adenocarcinomas of the endometrium Most common gynecologic malignancy in developed countries Second most common in developing countries. Adenocarcinomas, grade 1 and 2 endometrioid
More informationAppendix 1: Regional Lymph Node Stations for Staging Esophageal Cancer
Appendix 1: Regional Lymph Node Stations for Staging Esophageal Cancer Locoregional (N stage) disease was redefined in the seventh edition of the AJCC Cancer Staging Manual as any periesophageal lymph
More information